Alexion Pharmaceuticals (ALXN) fired its CEO and chief financial, as it is in the midst of an internal investigation looking into allegations of improper sales practices connected with its top selling drug Soliris. Soliris sales have totaled $2.2 billion in the first three quarters of the year. Alexion also said its 10-Q filling for the third quarter will now be filed in January. An Alexian Board member, David Brennan, is taking over immediately as interim CEO. He is a former CEO at AstraZeneca (AZN) .
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.